INDUSTRY SYMPOSIUM TIMETABLE
Friday, December 5, 2014
|
||||
|
Hall A
Infertility
|
Hall B
Fetomaternal
|
Hall C
Reproduction
|
Hall E
Fetomaternal
|
|
| 08:30-10:00 |
- Supported by IBSA Educational Program
|
- Supported by Perkin Elmer
|
||
| 10:20-11:50 | INNOVATION AND QUALITY: FROM STIMULATION TO PREGNANCY (Con't) | |||
| 12:10-13:40 |
- Supported by Roche
|
|||
| 14:30-16:00 | PRENATAL DIAGNOSIS IN THE ERA OF NIPT - Supported by Illumina |
Supportetd by Actavis
|
||
| 16:30-18:00 |
- Supported by Roche
|
|||
Saturday, December 6, 2014
|
||
|
Hall A
Infertility
|
Hall C
Reproduction
|
|
| 12:10-13:40 | 12:10-12:40 Genea embryo review incubator - Supported lecture by Genea Biomedx |
- Supported by Gedeon Richter
|
| 14:30-15:00 | Clinical Applications of oocyte and embryo Vitrification - Supported lecture by Kitazato |
|
INFERTILITY SESSIONS (Hall A)
FRIDAY, DECEMBER 5, 2014
|
08:30-10:00
|
IBSA Educational program
|
|
Capsule
|
The IBSA Educational workshop will host distinguished experts presenting innovations in clinical and laboratory aspects
|
|
Chairpersons
|
Bart C.J.M Fauser, Netherlands Rene Frydman, France |
|
|
Endocrinology
Understanding steroids in clinical practice
Philippe Bouchard, France
Thyroid Function and ART
Brigitte Velkeniers, Belgium
|
|
|
Biology
Developmental origins of ovarian reserve
Nick S. Macklon, UK
|
FETOMATERNAL SESSIONS (Hall B)
08:30-10:00
|
Supported by Perkin Elmer
|
|
Chairperson
|
Dietmar Schlembach, Germany
|
|
Pre-eclampsia prediction: Combined screening at 11-13 weeks
Jacques Jani, Belgium
|
|
|
Prevention of pre-eclampsia and IUGR with aspirin
Emmanuel Bujold, Canada
|
|
|
Screen and prevention of Preeclampsia - The health economic perspective
Dietmar Schlembach, Germany
|
12:10-13:40
|
ANGIOGENIC FACTORS IN PREECLAMPSIA: DIAGNOSIS, PREDICTION AND IMPACT ON CLINICAL MANAGEMENT (Hall B)
Supported by Roche
|
|
Capsule |
Increasingly, data are demonstrating the importance of angiogenic factors in the clinical management of preeclampsia. In this session new data from 2 important clinical studies will be presented. The PROGNOSIS study demonstrates the use of sFlt-1/PlGF ratio in prediction of short-term outcome in pregnant women with suspected preeclampsia. The PreOS study is an open study assessing the impact of the angiogenic factors in the routine clinical management of patients
|
| Chairperson | Harald Zeisler, Austria Shaun Brennecke, Australia |
|
Preeclampsia and angiogenic factors: An overview
Elisa Llurba Olivé, Spain |
|
| PROGNOSIS Study results: The prediction of short term outcome in pregnant women with suspected preeclampsia Stefan Verlohren, Germany |
|
| PreOS study results: Influence of sFIt-1 and PIGF on decision-making of physicians in pregnant women with suspicion of preeclampsia Holger Stepan, Germany |
14:30-16:00
|
Supported by Illumina
|
| Capsule |
Since its initial introduction into the prenatal screening/testing spectrum of care, the field of non-invasive prenatal testing (NIPT) has evolved and expanded rapidly. Although originally developed for autosomal aneuploidy detection of chromosomes 21, 18 and 13 in the high-risk pregnancy population, NIPT using genome-wide massively parallel sequencing of cell free DNA in maternal plasma also has the potential to expand testing beyond these common aneuploidies and beyond the high risk pregnancy population. Since its inception, testing for certain sex chromosome aneuploidies and certain microdeletions already has become possible. As this testing continues to evolve and expand, it prompts the question of what does the future hold for NIPT. This session will address the following questions about expanding the technology: Can this testing be expanded to the general obstetrical population? Can this testing be expanded beyond chromosomes 21, 18, 13, X and Y?. In addition, the challenges faced by clinicians are also an important aspect of this rapidly evolving field; therefore, this session also will address considerations for incorporating NIPT into the general obstetric practice, as well as the nuances around NIPT results. |
| Chairpersons |
Nan Okun, Canada
Mark Evans, USA
|
| NIPT in the general obstetrical population: Results, lessons and insights from the CARE study Sucheta Bhatt, USA |
|
| Clinical considerations for incorporating NIPT into your practice Eran Borenstein, USA |
|
| Biological considerations of discordant results and test failures Steven Warsof, USA |
|
|
Potential expansion of NIPT: Microdeletion panels to the whole genome panels and beyond
Yuval Yaron, Israel |
REPRODUCTION SESSION (Hall C)
14:30-15:30
|
Supportetd by Actavis
|
| Chairpersons |
Bart C.J.M. Fauser, Netherlands
Jacques Cohen, USA
|
|
Relevance of embryo competence for successful IVF, and role of GCSF
Bart C.J.M. Fauser , Netherlands
|
|
|
Diafert test in the daily laboratory practice
Fabian Somers
|
|
|
Discussion
|
REPRODUCTION SESSION (Hall E)
16:30-18:00
|
MEET THE EXPERT SESSION - ANGIOGENIC FACTORS: HOW CAN THEY INFLUENCE PATIENT MANGEMENT? (Hall E)
|
| Capsule |
Angiogenic factors are increasingly important in the management of patients with suspected preeclampsia. In this session investigators from the PreOS study will present clinical cases illustrating the impact of sFIt-1/PIGF ratio on patient management. |
| Moderator |
Holger Stepan, Germany |
| Presenters |
Dietmar Schlembach, Germany
Angela Ramoni, Austria
|
SATURDAY, DECEMBER 6, 2014
INFERTILITY SESSION (Hall A)
14:30 - 16:00 |
OOCYTE FREEZING
|
| Chairpersons |
Jacques Cohen, USA
Michael Grynberg, France
|
|
Clinical applications of oocyte and embryo virtification
Dominic Stoop, Belgium
|
|
|
Vitrified oocytes and embryo banking
Ana Cobo, Spain
|
|
|
Effects on gene expression in vitrification and slow freezing
Samir Hamamah, France
|
REPRODUCTION SESSION (Hall C)
12:10-13:40
|
FIBROIDS IN OB/GYN AND INFERTILITY (Hall C) Supported by Gedeon Richter/Preglem |
| Capsule |
Effective surgical management of endoscopic symptomatic fibroids requires extreme surgical skills. Specific Progesterone Receptor Modulators (SPRMs) are emerging as effective treatment in reducing fibroid size and delaying surgical treatment, but do they have a place in managing symptomatic fibroids before infertility treatments? |
| Chairpersons |
Bart C.J.M. Fauser, Netherlands
Attila Vereczkey, Hungary Jacques Donnez, Belgium |
|
SPRMs mechanism of action on fibroids
Philippe Bouchard, France
|
|
|
Surgical or medical treatment for fibroids?
Jacques Donnez, Belgium
|
|
|
Limitation of laparoscopic myomectomy
Rudi Campo, Belgium |
|
|
Hysteroscopic myomectomy in infertility: Limitations and complications
Jacques Hamou, France |